yahoo_financeOriginal article
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Phase 3KSI-501Positive
AI Analysis
Summary
Kodiak Sciences announced the first patient enrollment in the global Phase 3 ALTO trial evaluating KSI-501 for diabetic macular edema treatment.
Clinical Trial Data
Phase
Phase 3
Importance:6/10
Sentiment:
0.60
Phase 3Clinical TrialDiabetic Macular EdemaALTO trialPatient Enrollment
Related Companies
Read the original article
Published by yahoo_finance on August 10, 2026 8:35 PM